Literature DB >> 8042882

False changes in CA 125 levels in ovarian cancer patients after infusion of OC125 fragments for diagnostic and therapeutic purpose.

J Reinsberg1, U Wagner, D Krebs.   

Abstract

The influence of human anti-OC125 antibodies formed after multiple infusions of OC125 F(ab')2 fragments on the apparent levels of CA 125 measured with four different tests were examined in two ovarian cancer patients. With the homologous Assay 1, involving only OC125 antibodies, false increases of CA 125 values were observed after infusion of OC125 fragments, which completely covered real CA 125. In contrast, with Assay 2, 3 and 4, which involve no OC125 antibodies as capture antibodies, only slight false increases occurred in the presence of very high anti-OC125 antibody concentrations. Interference was eliminated by addition of non-specific murine IgG in Assay 2 and 4, but not in Assay 1 and 3 indicating that the false increases in Assay 1 and 3 were caused by anti-idiotypic anti-OC125 antibodies. In the presence of elevated real CA 125, with Assay 2 and to a considerably lesser degree with Assay 4, an inhibitory effect of anti-OC125 antibodies became evident leading to false decreases of CA 125 values. In Assay 4 reduction of assay response was eliminated by addition of nonspecific murine IgG. The results confirm that all available CA 125 tests are influenced by interference with human anti-OC125 antibodies. Thus, CA 125 levels in patients who have been treated with OC125 fragments should be interpreted with care.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8042882     DOI: 10.1007/bf02390669

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  19 in total

1.  New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope.

Authors:  T J O'Brien; L M Raymond; G A Bannon; D H Ford; H Hardardottir; F C Miller; J G Quirk
Journal:  Am J Obstet Gynecol       Date:  1991-12       Impact factor: 8.661

2.  Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network.

Authors:  U A Wagner; P F Oehr; J Reinsberg; S C Schmidt; H W Schlebusch; B Schultes; A Werner; G Prietl; D Krebs
Journal:  Biotechnol Ther       Date:  1992

3.  Heterophilic antibodies: a problem for all immunoassays.

Authors:  L M Boscato; M C Stuart
Journal:  Clin Chem       Date:  1988-01       Impact factor: 8.327

4.  Evaluation of serum CA 125 levels in the monitoring of ovarian cancer.

Authors:  I B Vergote; O P Børmer; V M Abeler
Journal:  Am J Obstet Gynecol       Date:  1987-07       Impact factor: 8.661

5.  Immunoscintigraphy using CA 125 antibodies in the management of ovarian cancer.

Authors:  J Brökelmann; A Bockisch; J Vogel; J Reinsberg; P Oehr; H J Biersack; D Krebs
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

6.  Idiotypic cascades after MAb OC125 application.

Authors:  J Reinsberg
Journal:  Hybridoma       Date:  1993-10

7.  Evidence for interaction of human anti-idiotypic antibodies with CA 125 determination in a patient after radioimmunodetection.

Authors:  J Reinsberg; A Heydweiller; U Wagner; K Pfeil; P Oehr; D Krebs
Journal:  Clin Chem       Date:  1990-01       Impact factor: 8.327

8.  Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types.

Authors:  S E Kabawat; R C Bast; W R Welch; R C Knapp; R B Colvin
Journal:  Am J Clin Pathol       Date:  1983-01       Impact factor: 2.493

9.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

10.  Recurrent idiotopes and internal images.

Authors:  N K Jerne; J Roland; P A Cazenave
Journal:  EMBO J       Date:  1982       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.